Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAWARD: Acetazolamide Timing for AMS Prevention
NCT03424226Phase 1Completed
- Sponsor
- Stanford University
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acetazolamide in acute mountain sickness (AMS) (2 arms), sponsored by Stanford University. Primary endpoint: Incidence of Acute Mountain Sickness at 2 days. Started Aug 2018; status: completed.
02
Drugs
acetazolamide
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT03424226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424226.